The novel therapy of this peptide represents a major advance in the management of type 2 diabetes. Distinct from existing therapies, tirzepatide affects dual pathways – glucagon-like peptide-1 (GLP-1) and GIP – https://tirzepatidepeptide146188.pages10.com/tirzepatide-peptide-a-new-frontier-in-diabetes-treatment-77465010